Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

This examination of individual safety reports from VigiBase found rechallenge with an immune checkpoint inhibitor following discontinuation due to an immune-related adverse event (irAE; data on n=452) was associated with the same irAE in 28.8% (95% CI 24.8-33.1) of cases.


JAMA Oncology